News Search Results
Feb 11, 2025, 06:55 ET Global Agriculture Industry Outlook worth $227.1 billion by 2029 - Exclusive Report by MarketsandMarkets™
yields and resource use, while organic practices prioritize ecological balance. In 2029, the emphasis on automated farm machinery, agriculture biotechnology, novel farming systems, organic and non-GMO seeds, are accelerating the agriculture industry growth. The agriculture industry is grappling with
More news about: MarketsandMarkets
Feb 10, 2025, 17:45 ET Origin Agritech Reports 24.6% Revenue Growth and Key Technological Milestones in Fiscal Year 2024
October 2024, Origin established the "Origin Marker Biological Breeding Service Consortium" with China Golden Marker Biotechnology Co., to accelerate licensing and commercialization of the GMO and gene editing technologies of the Company; andThe consortium established
More news about: Origin Agritech Limited
Feb 10, 2025, 17:31 ET American Association for Cancer Research Annual Meeting 2025: Stay Ahead with Real-Time AACR Conference Coverage and Expert Analysis from DelveInsight
providing a valuable platform for the oncology community to share and discuss the latest advancements in cancer research. Leading pharmaceutical and biotechnology companies will present cutting-edge clinical trial results, with specialized sessions such as "New Drugs on the Horizon" introducing innovative
More news about: DelveInsight Business Research, LLP
Feb 10, 2025, 17:00 ET Convergent Therapeutics Announces Two Clinical Trial Updates on CONV01-α at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025
Feb. 10, 2025 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced clinical trial updates for
More news about: Convergent Therapeutics
Feb 10, 2025, 16:05 ET Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
Feb. 10, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced a corporate restructuring to focus on the advancement
More news about: Q32 Bio
Feb 10, 2025, 16:00 ET Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with Osteoarthritis
2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful outcome from the compassionate treatment of a female donkey with its innovative liposomal CBD
More news about: Innocan Pharma Corporation
Feb 10, 2025, 16:00 ET Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with Osteoarthritis
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful outcome from the compassionate treatment of a female donkey with its innovative liposomal CBD
More news about: Innocan Pharma Corporation
Feb 10, 2025, 11:30 ET Graphene Market Size to Register a Robust CAGR of 24% in 2023-2031 Driven by Rising Demand for Graphene Composites
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Feb 10, 2025, 10:04 ET IgGenix to Present Alpha-gal Syndrome Monoclonal Antibody Discovery at 2025 AAAAI / WAO Joint Congress
Calif., Feb. 10, 2025 /PRNewswire/ -- IgGenix, Inc., a clinical-stage biotechnology company pioneering innovative treatments for immune-mediated diseases, today announced the upcoming presentation of new data at the 2025 American
More news about: IgGenix
Feb 10, 2025, 10:00 ET TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
Feb. 10, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the first Cohort B patient
More news about: TC BioPharm
Feb 10, 2025, 08:05 ET Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
MEETING, Pa., Feb. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Feb 10, 2025, 08:00 ET Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of America
Intas' biosimilars are manufactured at Intas Pharmaceuticals' state of the art European Union- Good Manufacturing Practices (EU-GMP) certified biotechnology plant located near Ahmedabad, Gujarat. For more information, visit us at
More news about: Bio-Thera Solutions, Ltd
Feb 10, 2025, 07:30 ET NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies
allogeneic cell products for the treatment of neurodegenerative diseases and potential cure for diabetes, are on a mission to create a leading biotechnology entity. The upcoming expected merger aims to transform the treatment landscape for complex conditions such as diabetes. By uniting the core competencies
More news about: Kadimastem Ltd.; NLS Pharmaceutics Ltd.
Feb 10, 2025, 07:00 ET IVIEW Therapeutics Announces Topline Results from Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe for Dry Eye Disease
N.J., Feb. 10, 2025 /PRNewswire/ -- IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced positive topline data from its Phase 1/2 clinical trial
More news about: IVIEW Therapeutics Inc.
Feb 10, 2025, 07:00 ET Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
the skin, leading to an immune reaction and inflammation. About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Feb 10, 2025, 06:00 ET IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
transactions representing more than $65 billion of value for biotechnology companies worldwide. Earlier in his career he worked as a Senior Staff Scientist at a private biotechnology company in San Diego and was a post-doctoral fellow at the
More news about: IDEAYA Biosciences, Inc.
Feb 10, 2025, 03:31 ET Bio-Based Resins Market to Grow by USD 6.19 Billion from 2025-2029, Rising Environmental Concerns Boosting Revenue, AI Redefining Market Landscape - Technavio
stability. Soybean-based formulations are also being used in eco-friendly materials for jars, bottles, and cups. Technological advancements in biotechnology and subsidies for renewable resources are driving the market forward. The use of bio-based feedstocks reduces environmental impact, ecological footprints,
More news about: Infiniti Research, Inc.
Feb 07, 2025, 21:24 ET Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence
Pisano will remain Interim CEO until the new CEO is hired. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
Feb 07, 2025, 17:13 ET Spyre Therapeutics Announces Grants of Inducement Awards
Feb. 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy
More news about: Spyre Therapeutics, Inc.
Feb 07, 2025, 16:01 ET AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Feb 07, 2025, 09:12 ET CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
KING OF PRUSSIA, Pa., Feb. 7, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety
More news about: CSL Behring
Feb 07, 2025, 09:00 ET Hemab Therapeutics Presents Interim Data from Ongoing Phase 2 Study of HMB-001 as First Ever Prophylactic Treatment in Glanzmann Thrombasthenia and Preclinical Data from HMB-002 in Von Willebrand Disease at the 2025 EAHAD Annual Congress
Mass., Feb. 7, 2025 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today presented interim data from
More news about: Hemab Therapeutics
Feb 07, 2025, 08:00 ET Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
complete clinical trials and submit applications for regulatory approvals; products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies; commercial acceptance of Palatin's products; and other factors discussed in Palatin's periodic filings with the SEC. All forward-looking
More news about: Palatin Technologies, Inc.
Feb 07, 2025, 06:55 ET Water Treatment Chemicals Market worth $46.64 billion by 2029 - Exclusive Report by MarketsandMarkets™
align with global efforts to minimize carbon footprints. Increasing adoption in the industrial and municipal sectors, coupled with advancements in biotechnology for enhanced performance, further drives the demand. As industries prioritize eco-friendly practices, bio-based chemicals gain traction as a practical
More news about: MarketsandMarkets
Feb 07, 2025, 06:45 ET Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company